Skip to main content
Themis Medicare Ltd. logo

Themis Medicare Ltd. — Investor Relations & Filings

Ticker · THEMISMED ISIN · INE083B01024 LEI · 335800LHRDVIKH69AF42 BSE.NS Manufacturing
Open in API
Filings indexed 710 across all filing types
Latest filing 2023-02-09 Regulatory Filings
Country IN India
Listing BSE.NS THEMISMED

About Themis Medicare Ltd.

https://www.themismedicare.com/

Themis Medicare Ltd. is a research-driven pharmaceutical organization specializing in the development, manufacture, and marketing of a diverse range of therapeutic products. The company focuses on high-value segments including pain management, anesthesia, critical care, anti-infectives, and oncology. Its core competencies lie in the production of Active Pharmaceutical Ingredients (APIs) and complex finished dosage formulations, particularly injectables. Themis Medicare maintains a strong emphasis on Research and Development, operating state-of-the-art facilities that adhere to international quality standards such as WHO-GMP. Through strategic partnerships and a robust supply chain, the company serves both domestic and international markets, providing specialized medical solutions for hospital-based care and chronic disease management. Its portfolio includes proprietary delivery systems and differentiated generic products designed to improve patient outcomes.

Recent filings

Filing Released Lang Actions
Reply to Clarification- Financial results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India providing clarification regarding the Limited Review Report for the quarter and nine months ended 31st December 2022. It mentions a correction related to the UDIN (Unique Document Identification Number) in the Limited Review Report issued by the Statutory Auditors. The document is short (1909 characters) and serves as a clarification or regulatory communication rather than the actual financial report or audit report itself. It does not contain financial statements or substantive financial data but rather addresses an issue related to the audit documentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and clarifications that do not fit other specific categories.
2023-02-09 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation Q3 & 9M FY23' and is addressed to stock exchanges (BSE and NSE) under SEBI regulations. It contains detailed company information, business overview, financial highlights, management team details, and strategic focus. The content is consistent with an investor presentation, which is a detailed presentation for investors focusing on financials, strategy, and market position. The document is about 15,000 characters long, indicating it is a full presentation rather than a brief announcement. There is no indication that this is an earnings release, annual report, or regulatory filing. Therefore, the appropriate classification is Investor Presentation (IP).
2023-02-09 English
Loss of Share Certificates
Regulatory Filings Classification · 100% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding an intimation under regulation 39(3) of SEBI (LODR) Regulations, 2015. It informs about the loss of a share certificate and the issuance of a duplicate share certificate. The content is a regulatory compliance notification related to share certificate handling and does not contain financial data, management discussion, or report publication. It is not an annual report, earnings release, or any financial report. It is also not a voting result, board change, or capital update. The document is a regulatory filing notifying the exchange about a procedural matter under listing obligations. Therefore, it fits best under Regulatory Filings (RNS). The document length is short and focused on compliance notification, confirming the classification.
2023-02-09 English
Price movement
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Ltd. providing a clarification regarding the recent price movement of Themis Medicare Limited's shares. It references a query from the exchange and explains that all material and price-sensitive information has been disclosed timely as per SEBI Listing Regulations. The document explicitly states that the price movement is market-driven and not due to any undisclosed information. There are no financial statements, report data, or detailed financial analysis present. The document is short (2203 characters) and serves as a regulatory clarification or announcement rather than a financial report or detailed filing. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements and clarifications that do not fit other categories.
2023-02-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a letter addressed to stock exchanges (BSE and NSE) informing about the rescheduling of an earnings conference call for Themis Medicare Limited. It references Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The document mentions the conference call will discuss operational and financial performance for Q3 & 9M FY23, but it does not contain any financial data or results itself. It is an announcement about the scheduling of a conference call, not the transcript or the earnings release. The document length is 3029 characters, which is relatively short and consistent with an announcement. Therefore, this document is best classified as a Call Transcript announcement or invitation, but since it is only an invitation and rescheduling notice, it fits best under Call Transcript (CT) category as it relates to the conference call event itself.
2023-02-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) informing about the rescheduling of an earnings conference call for Themis Medicare Limited. It references Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The document includes details about the new date and time for the earnings call and provides dial-in information and management representatives who will participate. There is no actual financial data or detailed financial report included, only an announcement about the scheduling of the earnings call. The document length is 3023 characters, which is relatively short and consistent with an announcement rather than a full transcript or report. Therefore, this document is best classified as a Call Transcript (CT) announcement or invitation, but since it is only an invitation and rescheduling notice, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about the earnings call schedule change, not the transcript itself.
2023-02-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.